Download JUVÉDERM® Before & After pictures that you can add to your own office material and website.
Download JUVÉDERM® XC logos for use on both printed and online materials.
Download the JUVÉDERM® XC Consumer Ad. The ad
will open in Adobe® Acrobat® Reader® in PDF format.
Download the JUVÉDERM® XC Patient Brochure.
*Vs the JUVÉDERM® XC 0.8 cc syringe.
†Clinically relevant HA is defined as highly cross-linked hyaluronic acid.
1. Data on file, Allergan, Inc.; Worldwide Dermal Facial Filler Market Overview, Q2 2011.
Please note: Documents are provided in Adobe® Reader® format (PDF). To view PDF documents, you must have the Adobe® Reader® software installed on your computer.
If you do not have Adobe® Reader®, download it from the Adobe® website.
* In the United States, JUVÉDERM® is indicated for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).
Ω Compared to the non-lidocaine JUVÉDERM® formulation.
‡This includes all JUVÉDERM® injectable gel formulations. Most subjects acquired optimal correction at initial treatment.
§When compared to the nonlidocaine JUVÉDERM® formulations.
¶Patient retention rates for JUVÉDERM® (n = 205),
Radiesse® (n = 74), and Restylane® (n = 227) based on patients with 3 visits.
1. Pinsky MA, Thomas JA, Murphy DK, Walker PS; for JUVÉDERM® vs ZYPLAST® Nasolabial Fold Study Group. JUVÉDERM® injectable gel: A multicenter, double-blind, randomized study of safety and effectiveness. Aesthetic Surg J. 2008;28(1):17-23.
2. Data on file, Allergan, Inc.
3. Weinkle SH, Bank DE, Boyd CM, Gold MH, Thomas JA, Murphy DK. A multi-center, double-blind, randomized controlled study of the safety and effectiveness of JUVÉDERM® injectable gel with and without lidocaine. J Cosmet Dermatol. 2009;8(3):205-210.
4. Data on file, Allergan, Inc., September 1, 2011; Dermal Filler Chart Retention Study.
5. Borrell M, Leslie DB, Tezel A. Lift capabilitites of hyaluronic acid fillers. J Cosmet Laser Ther. 2011:13(1):21-27.
Please note that altering the downloadable files in any way is not permissable, and that Allergan is not responsible
for any technical issues related to installing or operating the tools. Allergan reserves the right to prevent the
use of these tools at any time and without notice.
These tools are not a substitute for a consultation with a qualified healthcare professional. When you decide
on and consult with aqualified healthcare professional, he/she will detemine the severity of your wrinkles and
folds and whether BOTOX® Cosmetic or JUVÉDERM® is right for you. He/she may
recommend a different treatment based on your individual needs to help you achive yourdesired result.
Allergan, www.BOTOXCosmetic.com and www.juvederm.com
are not engaged in providing medical advice or services, and do not endorse or warrant any specific technique,
method or treatment, or outcome. It is up to your individual healthcare professional to use his/her best
medical judgment when making recommendations and determining appropriate patient care.
JUVÉDERM® is part of the ALLERGAN® Portfolio of Products, and this is the JUVÉDERM® website. For information on BOTOX® Cosmetic (onabotulinumtoxinA), visit BotoxCosmetic.com.
JUVÉDERM® injectable gel is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).
IMPORTANT SAFETY INFORMATION
JUVÉDERM® injectable gel should not be used in patients who have severe allergies marked by a history of anaphylaxis or history or presence of multiple severe allergies. JUVÉDERM® should not be used in patients with a history of allergies to Gram-positive bacterial proteins. JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC should not be used in patients with a history of allergies to lidocaine.
JUVÉDERM® injectable gel should not be injected into blood vessels. If there is an active inflammatory process or infection at specific injection sites, treatment should be deferred until the underlying process is controlled.
The safety of JUVÉDERM® for use during pregnancy, in breast-feeding females, or in patients under 18 years has not been established. The safety and effectiveness of JUVÉDERM® injectable gel for the treatment of areas other than facial wrinkles and folds (such as lips) have not been established in controlled clinical studies.
Patients who are using substances that can prolong bleeding, such as aspirin or ibuprofen, as with any injection, may experience increased bruising or bleeding at injection site. Patients should inform their physician before treatment if they are using these types of substances. As with all skin-injection procedures, there is a risk of infection.
JUVÉDERM® should be used with caution in patients on immunosuppressive therapy, or therapy used to decrease the body's immune response, as there may be an increased risk of infection. The safety of JUVÉDERM® in patients with a history of excessive scarring (eg, hypertrophic scarring and keloid formations) and pigmentation disorders has not been studied.
If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment with JUVÉDERM® injectable gel, or if JUVÉDERM® is administered before the skin has healed completely after such a procedure, there is a possible risk of an inflammatory reaction at the treatment site.
The most commonly reported side effects are temporary injection-site redness, swelling, pain/tenderness, firmness, lumps/bumps, and bruising. Most side effects are mild or moderate in nature, and their duration is short lasting (7 days or less).
To report a problem with JUVÉDERM®, please call Allergan Product Surveillance at 1-800-624-4261.
For more information, please see the About Safety page at www.juvederm.com or call the Allergan Product Support line at 1-800-433-8871.
JUVÉDERM® injectable gel is available by prescription only.
BOTOX® Cosmetic (onabotulinumtoxinA) Important Information
BOTOX® Cosmetic (onabotulinumtoxinA) for injection is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients ≤ 65 years of age.
IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING
WARNING: DISTANT SPREAD OF TOXIN EFFECTPostmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses, including spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses.
CONTRAINDICATIONSBOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.
WARNINGS AND PRECAUTIONS
Lack of Interchangeability between Botulinum Toxin ProductsThe potency Units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of BOTOX® Cosmetic cannot be compared to nor converted into units of any other botulinum toxin products assessed with any other specific assay method.
Spread of Toxin EffectPlease refer to Boxed Warning for Distant Spread of Toxin Effect.
No definitive, serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines) have been reported.
Injections In or Near Vulnerable Anatomic Structures
Care should be taken when injecting in or near vulnerable anatomic structures. Serious adverse events including fatal outcomes have been reported in patients who had received BOTOX® injected directly into salivary glands, the oro-lingual-pharyngeal region, esophagus and stomach. Safety and effectiveness have not been established for indications pertaining to these injection sites. Some patients had preexisting dysphagia or significant debility. Pneumothorax associated with injection procedure has been reported following the administration of BOTOX® near the thorax. Caution is warranted when injecting in proximity to the lung, particularly the apices.
Hypersensitivity ReactionsSerious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such reactions occur, further injection of BOTOX® Cosmetic should be discontinued and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.
Cardiovascular SystemThere have been reports following administration of BOTOX® of adverse events involving the
cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some
of these patients had risk factors including pre-existing cardiovascular disease. Use caution when
administering to patients with pre-existing cardiovascular disease.
Pre-existing Neuromuscular DisordersIndividuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of BOTOX® Cosmetic.
This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin.
Pre-existing Conditions at the Injection Site
Caution should be used when BOTOX® Cosmetic treatment is used in the presence of inflammation at
the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s);
and when used in patients who have marked facial asymmetry, ptosis, excessive dermatochalasis, deep
dermal scarring, thick sebaceous skin or the inability to substantially lessen glabellar lines by physically
spreading them apart.
ADVERSE REACTIONSThe most frequently reported adverse events following injection of BOTOX® Cosmetic include
blepharoptosis and nausea.
Co-administration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like nondepolarizing blockers, lincosamides, polymyxins, quinidine, magnesium sulfate, anticholinesterases, succinylcholine chloride) should only be performed with caution as the effect of the toxin may be potentiated.
Use of anticholinergic drugs after administration of BOTOX® Cosmetic may potentiate systemic anticholinergic effects.
The effect of administering different botulinum neurotoxin serotypes at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX® Cosmetic.
USE IN SPECIFIC POPULATIONS
BOTOX® Cosmetic is not recommended for use in children or pregnant women.
Please see BOTOX® Cosmetic full Prescribing Information including Boxed Warning and Medication Guide.
The NATRELLE® Collection of Breast Implants is indicated for females for breast augmentation and breast reconstruction.
From the UK? Visit www.juvedermultra.co.uk.
©2012 Allergan, Inc. ® and ™ marks owned by Allergan, Inc. JUVÉDERM® mark owned by Allergan Industrie, SAS.
Acrobat, Adobe, and Reader are registered trademarks of Adobe Systems Incorporated in the
United States and/or other countries. Radiesse is a registered trademark of Merz Aesthetics, Inc. Restylane is a registered trademark of HA North American Sales AB.